Orgenesis's Days Sales Outstanding for the
three
months ended in Dec. 2021 was 206.51.
Orgenesis's Days Inventory for the
three
months ended in Dec. 2021 was 1.37.
Orgenesis's Days Payable for the
three
months ended in Dec. 2021 was 45.26.
Therefore, Orgenesis's Cash Conversion Cycle (CCC) for the
three
months ended in Dec. 2021 was 162.62.
Orgenesis Cash Conversion Cycle Historical Data
The historical data trend for Orgenesis's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Orgenesis Annual Data
Trend
Nov12
Nov13
Nov14
Nov15
Nov16
Nov17
Nov18
Dec19
Dec20
Dec21
Cash Conversion Cycle
-150.47
-36.00
167.74
34.53
6.19
Orgenesis Quarterly Data
Feb17
May17
Aug17
Nov17
Feb18
May18
Aug18
Nov18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Cash Conversion Cycle
13.20
-94.21
31.78
123.32
162.62
Competitive Comparison
For the Biotechnology subindustry, Orgenesis's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orgenesis Cash Conversion Cycle Distribution
For the Biotechnology industry and Healthcare sector, Orgenesis's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Orgenesis's Cash Conversion Cycle falls into.
Orgenesis Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Orgenesis's Cash Conversion Cycle for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Orgenesis Cash Conversion Cycle Related Terms
Thank you for viewing the detailed overview of Orgenesis's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.03(1.45%) Volume: 4,849 9:50AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ORGS has been successfully added to your 
